Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Debajit K Biswas"'
Autor:
Bose S Kochupurakkal, Zhigang C Wang, Tony Hua, Aedin C Culhane, Scott J Rodig, Koraljka Rajkovic-Molek, Jean-Bernard Lazaro, Andrea L Richardson, Debajit K Biswas, J Dirk Iglehart
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0140243 (2015)
Both oncogenic and tumor-suppressor activities are attributed to the Nuclear Factor kappa B (NF-kB) pathway. Moreover, NF-kB may positively or negatively regulate proliferation. The molecular determinants of these opposing roles of NF-kB are unclear.
Externí odkaz:
https://doaj.org/article/e2c8ac55fb3a48a5adfcf77cafd2d682
Autor:
Debajit K. Biswas, J. Dirk. Iglehart, Myles Brown, Alexander Miron, Teresa Bowman, Kathleen M. Foley, Ruiyang Tian, Scott. J. Rodig, Gautam Maulik, Bose Kochupurakkal, Yoon J. Choi, Penelope L. Miron, Shannon T. Bailey
Breast cancers with HER2 overexpression are sensitive to drugs targeting the receptor or its kinase activity. HER2-targeting drugs are initially effective against HER2-positive breast cancer, but resistance inevitably occurs. We previously found that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f36413cd5f35e3b13b71c7b9413ebc2
https://doi.org/10.1158/1541-7786.c.6539457
https://doi.org/10.1158/1541-7786.c.6539457
Autor:
Debajit K. Biswas, J. Dirk. Iglehart, Myles Brown, Alexander Miron, Teresa Bowman, Kathleen M. Foley, Ruiyang Tian, Scott. J. Rodig, Gautam Maulik, Bose Kochupurakkal, Yoon J. Choi, Penelope L. Miron, Shannon T. Bailey
PDF file - 78K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fbc4335ca11a30aa40bb5c5aaae5e9b
https://doi.org/10.1158/1541-7786.22509957.v1
https://doi.org/10.1158/1541-7786.22509957.v1
Autor:
Debajit K. Biswas, J. Dirk. Iglehart, Myles Brown, Alexander Miron, Teresa Bowman, Kathleen M. Foley, Ruiyang Tian, Scott. J. Rodig, Gautam Maulik, Bose Kochupurakkal, Yoon J. Choi, Penelope L. Miron, Shannon T. Bailey
PDF file - 669K, Figure S1. FACS sorting of HER2-enriched fraction of SKBR3 and analysis of same by FACS in parental derivatives. Figure S2. Inhibition of HER2 signaling by Lapatinib in SKR6 and SKR6LR cells. Figure S3. Xenograft histopathology. Figu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67751a23ec71a28f94f2db055839ff16
https://doi.org/10.1158/1541-7786.22509954
https://doi.org/10.1158/1541-7786.22509954
Autor:
Debajit K. Biswas, J. Dirk Iglehart, Arthur B. Pardee, Marek J. Palczewski, Shannon T. Bailey, Qian Shi, Sindhu Singh
Nuclear factor-κB (NF-κB), a transcription factor with pleotropic effects, is a downstream mediator of growth signaling in estrogen receptor (ER)-negative and erbB family particularly erbB2 (HER-2/neu) receptor–positive cancer. We previously repo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa0786e31419812835c11fb1ab3830b0
https://doi.org/10.1158/1535-7163.c.6532602.v1
https://doi.org/10.1158/1535-7163.c.6532602.v1
Autor:
Debajit K. Biswas, J. Dirk Iglehart, Arthur B. Pardee, Marek J. Palczewski, Shannon T. Bailey, Qian Shi, Sindhu Singh
Supplementary Fig. S1 from Nuclear factor-κB activation: a molecular therapeutic target for estrogen receptor–negative and epidermal growth factor receptor family receptor–positive human breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::965534c87f4e0a55c573571408936bfb
https://doi.org/10.1158/1535-7163.22487883.v1
https://doi.org/10.1158/1535-7163.22487883.v1
Autor:
Debajit K. Biswas, J. Dirk Iglehart, Arthur B. Pardee, Marek J. Palczewski, Shannon T. Bailey, Qian Shi, Sindhu Singh
Supplementary Table S1 from Nuclear factor-κB activation: a molecular therapeutic target for estrogen receptor–negative and epidermal growth factor receptor family receptor–positive human breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edd437730cda36dd2309c3bbb644ea02
https://doi.org/10.1158/1535-7163.22487877
https://doi.org/10.1158/1535-7163.22487877
Autor:
Debajit K. Biswas, J. Dirk Iglehart, Arthur B. Pardee, Marek J. Palczewski, Shannon T. Bailey, Qian Shi, Sindhu Singh
Supplementary Fig. S1 legend from Nuclear factor-κB activation: a molecular therapeutic target for estrogen receptor–negative and epidermal growth factor receptor family receptor–positive human breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7c7e4febdb1750aef245026df9871b0
https://doi.org/10.1158/1535-7163.22487880.v1
https://doi.org/10.1158/1535-7163.22487880.v1
Publikováno v:
BioTechniques, Vol 29, Iss 5, Pp 1056-1064 (2000)
The level of estrogen receptor (ER) is a key determinant for the management of ERpositive [ER(+)] breast cancer patients. Growth of many human breast cancers is regulated by estrogen (E2) and progesterone (Pr). Generally, the ER in ER(+) breast cance
Externí odkaz:
https://doaj.org/article/4269eed73e594dc690a1bec5da22c73f
Autor:
Ruiyang Tian, Penelope Miron, Gautam Maulik, Scott J. Rodig, Bose Kochupurakkal, Alexander Miron, Debajit K. Biswas, Shannon T. Bailey, Teresa V. Bowman, Kathleen M. Foley, Yoon Jong Choi, J. Dirk Iglehart, Myles Brown
Publikováno v:
Molecular Cancer Research. 12:408-420
Breast cancers with HER2 overexpression are sensitive to drugs targeting the receptor or its kinase activity. HER2-targeting drugs are initially effective against HER2-positive breast cancer, but resistance inevitably occurs. We previously found that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::692427f87b44f0c9cf18504ceca7a1eb
https://doi.org/10.1158/1541-7786.mcr-13-0206-t
https://doi.org/10.1158/1541-7786.mcr-13-0206-t